Another email i've sent to Michael Frank. I finally got a reply. (Honestly, i don't care if it looks like i'm being pushy.)
Mr. Michael Frank,
Over the past few days I’ve sent multiple emails inquiring about the status of the completion of the first 210 patient enrollment, mainly if the enrollment of the first 210 patients has been met.
Reiterated -
((In a Press Release on October 25, 2020 the Company stated that, “it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020”.
In a Press Release on December 23, 2020 the Company stated that, “the Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization”.
We’re now in the latter part of January 2021. Has the 210 patients threshold been met? If so, is the DSMB now in the process of reviewing the data and will the Company publicly release the results?))
I understand a person in your position is probably extremely busy. However, it does not exactly instill shareholder confidence to have emails that go unanswered. If you’re unable to provide any meaningful answers at this time a simple reply of “no comment” would certainly go a long way than no reply at all.
Thank you,
xxxxx xxxxxxxxx
Revive Therapeutics Shareholder
His reply...
On Jan 28, 2021, at 3:44 PM, Michael Frank
<mfrank@revivethera.com> wrote:
It’s a Phase 3 double blinded study
Do you understand what that is ?
As you see on clinicaltrials.gov the study is progressing well and progressing
Thank you for your support
That’s all that can be said now
Michael Frank
CEO
Revive Therapeutics Inc.
